CASP3 and Alzheimer disease: Given the prominence of Aβ and inflammation as targets for AD drug development (van Bokhoven et al., 2021), inhibiting caspase-3 activity offers a potential alternative therapeutic strategy that could complement and enhance current treatment approaches.